LAVAL, QC, April 21, 2026 /CNW/ - In recognition of AML World Awareness Day, Servier Canada is highlighting the progress made in precision medicine for Acute Myeloid Leukemia (AML). With TIBSOVO(R) ...
Genomic profiling enables therapy individualization when actionable mutations (FLT3, NPM1, IDH1/2, TP53) are present, moving ...
Sellas Life Sciences’ investigational CDK9 inhibitor has scored in a midstage acute myeloid leukemia (AML) study, demonstrating an overall response rate (ORR) more than double the 20% goal. The ...
(RTTNews) - Shares of SELLAS Life Sciences Group Inc. (SLS) are up nearly 7% at $1.86 in premarket trading, following promising clinical data from its ongoing Phase 2 study of SLS009 in ...
・Topline data for the trial is expected by Q4 2026. SELLAS Life Sciences Group, Inc. (SLS) on Thursday said it has enrolled its first patient in a Phase 2 trial of SLS009 (tambiciclib), a selective ...
CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Syros Pharmaceuticals (NASDAQ:SYRS), a biopharmaceutical company committed to advancing new standards of care for the frontline treatment of hematologic ...
Sellas (NASDAQ:SLS) reported positive data from a Phase 2 study of its drug SLS009 in the treatment of patients with relapsed/refractory acute myeloid leukemia, or AML, with ASXL1 mutations. The study ...
CPX-351 showed a 49% CR/CRi rate in older patients with secondary or high-risk AML, with 67% achieving MRD negativity. Early mortality was higher, and fewer patients underwent allo-HSCT compared to ...
A new Phase 1B/2 trial treated patients with acute myeloid leukemia (AML) in a drug regimen combination of Annamycin and Ara-C. The evaluation of Annamycin in combination with Ara-C (cytarabine) has ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results